Dissecting tumor responsiveness to immunotherapy: the experience of peptide-based melanoma vaccines. (Q35595698)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14643925%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

review article

1 reference

title

Dissecting tumor responsiveness to immunotherapy: the experience of peptide-based melanoma vaccines (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14643925%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14643925%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

5

Francesco M Marincola

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14643925%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

author name string

Simone Mocellin

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14643925%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Donato Nitti

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14643925%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Mario Lise

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14643925%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

language of work or name

English

0 references

publication date

1 December 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14643925%20AND%20SRC:MED&resulttype=core&format=json

Biochimica et Biophysica Acta

21 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14643925%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

volume

1653

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14643925%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14643925%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

page(s)

61-71

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14643925%20AND%20SRC:MED&resulttype=core&format=json

Cancer immunoediting: from immunosurveillance to tumor escape

21 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Antibodies against p53 are associated with poor prognosis of colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Human tumor antigens recognized by T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillanc

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

T-cell clones that react against autologous human tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Viruses, cancer and AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Post-transplant malignancy: the role of immunosuppression

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Cytokines and immune response in the tumor microenvironment

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Progress in human tumour immunology and immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

A listing of human tumor antigens recognized by T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Peptide-based cancer vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

The role of CD4+ T cell responses in antitumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

CD4 T cells and their role in antitumor immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Expression of the co-stimulatory molecule B7 on melanoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Human dendritic cells, pulsed with either melanoma tumor cell lysates or the gp100 peptide(280-288), induce pairs of T-cell cultures with similar phenotype and lytic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Phenotypic analysis of antigen-specific T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Status of activation of circulating vaccine-elicited CD8+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Cytotoxic T-cell induction in metastatic melanoma patients undergoing recombinant vaccinia virus-based immuno-gene therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Functional heterogeneity of vaccine-induced CD8(+) T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Differential Anti-MART-1/MelanA CTL Activity in Peripheral Blood of HLA-A2 Melanoma Patients in Comparison to Healthy Donors

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Circulating Melan-A/Mart-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Genetic instabilities in human cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

A natural history of melanoma: serial gene expression analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

High-fidelity mRNA amplification for gene profiling.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Exploring the new world of the genome with DNA microarrays

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Quantitative imaging of the T cell antitumor response by positron-emission tomography.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Two subsets of memory T lymphocytes with distinct homing potentials and effector functions

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

A tumor-infiltrating lymphocyte from a melanoma metastasis with decreased expression of melanoma differentiation antigens recognizes MAGE-12.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

In vivo tracking of tumor-specific T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Short-term kinetics of tumor antigen expression in response to vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Kinetics of cytokine expression in melanoma metastases classifies immune responsiveness

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Quantitative real-time PCR: a powerful ally in cancer research.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

A polyadenylate binding protein localized to the granules of cytolytic lymphocytes induces DNA fragmentation in target cells

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Mechanisms of interleukin-10-mediated immune suppression

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Interleukin-10 and the interleukin-10 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

IL-10 expression by CT26 colon carcinoma cells inhibits their malignant phenotype and induces a T cell-mediated tumor rejection in the context of a systemic Th2 response

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

The dual role of IL-10.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Tolerance, danger, and the extended family

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

A fresh look at tumor immunosurveillance and immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Induction of tumor-specific T cell memory by NK cell–mediated tumor rejection

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Histamine dihydrochloride: inhibiting oxidants and synergising IL-2-mediated immune activation in the tumour microenvironment

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Interleukin-10-mediated Inhibition of free radical generation in macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Macrophage deactivation by interleukin 10

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Histamine: a novel approach to cancer immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0304-419X%2803%2900032-5

7 January 2021

10.1016/S0304-419X(03)00032-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14643925%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

1 reference